Jackson D, Ran D, Zhang F, Ouwens M, Druker V, Sweeting M
Pharm Stat. 2025; 24(1):e2462.
PMID: 39905716
PMC: 11794985.
DOI: 10.1002/pst.2462.
Gorrod H, Mt-Isa S, Xuan J, Vandormael K, Malbecq W, Yorke-Edwards V
Stat Methods Med Res. 2025; 34(2):322-335.
PMID: 39819221
PMC: 11874486.
DOI: 10.1177/09622802241300049.
Nathan S, Johri S, Joly J, King C, Raina A, McEvoy C
Thorax. 2023; 79(4):301-306.
PMID: 37979971
PMC: 10958253.
DOI: 10.1136/thorax-2023-220821.
Smith C, Kasza J, Woods R, Lockery J, Kirpach B, Reid C
Am J Epidemiol. 2023; 192(12):2063-2074.
PMID: 37552955
PMC: 10988226.
DOI: 10.1093/aje/kwad168.
Cro S, Morris T, Kahan B, Cornelius V, Carpenter J
BMC Med Res Methodol. 2020; 20(1):208.
PMID: 32787782
PMC: 7422467.
DOI: 10.1186/s12874-020-01089-6.
Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding.
Latimer N, White I, Tilling K, Siebert U
Stat Methods Med Res. 2020; 29(10):2900-2918.
PMID: 32223524
PMC: 7436445.
DOI: 10.1177/0962280220912524.
Estimation of treatment effects and model diagnostics with two-way time-varying treatment switching: an application to a head and neck study.
Chen Q, Zhang F, Chen M, Cong X
Lifetime Data Anal. 2020; 26(4):685-707.
PMID: 32125594
PMC: 7483904.
DOI: 10.1007/s10985-020-09495-0.
Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
Latimer N, Abrams K, Siebert U
BMC Med Res Methodol. 2019; 19(1):69.
PMID: 30935369
PMC: 6444622.
DOI: 10.1186/s12874-019-0709-9.
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G, Royle K, OConnor S, Cairns D, Ashcroft A, Williams C
Br J Haematol. 2019; 185(3):450-467.
PMID: 30729512
PMC: 6519200.
DOI: 10.1111/bjh.15782.
Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?.
Latimer N, White I, Abrams K, Siebert U
Stat Methods Med Res. 2018; 28(8):2475-2493.
PMID: 29940824
PMC: 6676341.
DOI: 10.1177/0962280218780856.
rpsftm: An R Package for Rank Preserving Structural Failure Time Models.
Allison A, White I, Bond S
R J. 2018; 9(2):342-353.
PMID: 29564164
PMC: 5858764.
A framework for the design, conduct and interpretation of randomised controlled trials in the presence of treatment changes.
Dodd S, White I, Williamson P
Trials. 2017; 18(1):498.
PMID: 29070048
PMC: 5657109.
DOI: 10.1186/s13063-017-2240-9.
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer.
Skaltsa K, Ivanescu C, Naidoo S, Phung D, Holmstrom S, Latimer N
Target Oncol. 2016; 12(1):111-121.
PMID: 27981431
PMC: 5253154.
DOI: 10.1007/s11523-016-0472-3.
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
Latimer N, Bell H, Abrams K, Amonkar M, Casey M
Cancer Med. 2016; 5(5):806-15.
PMID: 27172483
PMC: 4864810.
DOI: 10.1002/cam4.643.
Gaining power and precision by using model-based weights in the analysis of late stage cancer trials with substantial treatment switching.
Bowden J, Seaman S, Huang X, White I
Stat Med. 2015; 35(9):1423-40.
PMID: 26576494
PMC: 4871231.
DOI: 10.1002/sim.6801.
Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.
Latimer N, Abrams K, Amonkar M, Stapelkamp C, Swann R
Oncologist. 2015; 20(7):798-805.
PMID: 26040620
PMC: 4492231.
DOI: 10.1634/theoncologist.2014-0429.
A causal model for longitudinal randomised trials with time-dependent non-compliance.
Becque T, White I, Haggard M
Stat Med. 2015; 34(12):2019-34.
PMID: 25778798
PMC: 4672693.
DOI: 10.1002/sim.6468.
Randomised controlled trials and clinical maternity care: moving on from intention-to-treat and other simplistic analyses of efficacy.
Welsh A
BMC Pregnancy Childbirth. 2013; 13:15.
PMID: 23324442
PMC: 3554494.
DOI: 10.1186/1471-2393-13-15.
Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.
Morden J, Lambert P, Latimer N, Abrams K, Wailoo A
BMC Med Res Methodol. 2011; 11:4.
PMID: 21223539
PMC: 3024998.
DOI: 10.1186/1471-2288-11-4.
Causal proportional hazards models and time-constant exposure in randomized clinical trials.
Loeys T, Goetghebeur E, Vandebosch A
Lifetime Data Anal. 2005; 11(4):435-49.
PMID: 16328570
DOI: 10.1007/s10985-005-5233-z.